Literature DB >> 11998955

Sentinel lymph node biopsy as a tool for the staging of ductal carcinoma in situ in patients with breast carcinoma.

Gábor Cserni1.   

Abstract

PURPOSE: Ductal carcinoma in situ (DCIS) of the breast is defined as stage 0 disease, but its diagnosis is subject to sampling errors. This study was conducted to assess the usefulness of sentinel lymph node biopsy (SLNB) for furnishing indirect evidence of the invasion of tumors diagnosed as DCIS.
METHODS: A total of 201 SLNB procedures performed using a peritumoral tracer, being either dye alone or dye plus 99mTc-labeled colloidal albumin, were reviewed. The cases of DCIS were selected for analysis, and the results were compared with published data.
RESULTS: Among ten cases of DCIS studied by SLNB, only one had micrometastatic nodal involvement, which was revealed by cytokeratin immunostaining, and was limited to the sentinel node. This was a large intermediate-grade micropapillary/cribriform-type DCIS.
CONCLUSION: These findings indicate that while SLNB may be a valuable tool for the staging of tumors diagnosed as DCIS, it should not be performed in all cases, but probably restricted to large, high-grade, or comedo-type intraductal carcinomas.

Entities:  

Mesh:

Year:  2002        PMID: 11998955     DOI: 10.1007/s005950200000

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  3 in total

1.  Is Sentinel Lymph Node Dissection Warranted for Patients with a Diagnosis of Ductal Carcinoma In Situ?

Authors:  Ashleigh M Francis; Christine E Haugen; Lynn M Grimes; Jaime R Crow; Min Yi; Elizabeth A Mittendorf; Isabelle Bedrosian; Abigail S Caudle; Gildy V Babiera; Savitri Krishnamurthy; Henry M Kuerer; Kelly K Hunt
Journal:  Ann Surg Oncol       Date:  2015-04-24       Impact factor: 5.344

2.  Sentinel lymph node biopsy in patients with breast ductal carcinoma in situ: Chinese experiences.

Authors:  Xiao Sun; Hao Li; Yan-Bing Liu; Zheng-Bo Zhou; Peng Chen; Tong Zhao; Chun-Jian Wang; Zhao-Peng Zhang; Peng-Fei Qiu; Yong-Sheng Wang
Journal:  Oncol Lett       Date:  2015-07-10       Impact factor: 2.967

3.  Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy.

Authors:  L M van Roozendaal; B Goorts; M Klinkert; K B M I Keymeulen; B De Vries; L J A Strobbe; C A P Wauters; Y E van Riet; E Degreef; E J T Rutgers; J Wesseling; M L Smidt
Journal:  Breast Cancer Res Treat       Date:  2016-04-15       Impact factor: 4.872

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.